TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...hibitor-tazemetostat-in-INI1-negative-tumors

Date: 05 Mar 2018
Presenter: Antoine Italiano
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...anced-HER2-Positive-Breast-or-Gastric-Cancer

MEDI4276 is a HER2-bispecific antibody targeting two different epitopes on HER2, with site-specific conjugation via maleimidocaproyl linker to a potent tubulysin-based microtubule inhibitor.

Date: 05 Mar 2018
Presenter: Mark Pegram
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Gastric Cancer, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...fractory-R-R-B-cell-Non-Hodgkin-Lymphoma-NHL

Patients (pts) with NHL experiencing early relapse (ER) within two years of initial diagnosis and those double refractory (DR) to both rituximab and chemotherapy have particularly poor outcomes (Casulo et al JCO 2015; Gopal et al.

Date: 05 Mar 2018
Presenter: Jean-Marie Michot
Resources: Abstract, Presentation, Webcast
Topics: Lymphomas, Cancer Immunology and Immunotherapy, Haematologic Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ents-and-causes-resistance-to-RAF-inhibitors

Date: 05 Mar 2018
Presenter: Azad Saei
Resources: Abstract
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

https://oncologypro.esmo.org/Meeting-Resour...3965-in-patients-with-advanced-solid-tumours

A key metabolic alteration in tumour cells is increased dependency on glycolysis, resulting in the production of lactate which is transported out of cells by MCTs.

Date: 05 Mar 2018
Presenter: Ruth Plummer
Resources: Abstract, Presentation, Webcast
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...abolism-drug-development-in-myeloid-diseases

Mutations in isocitrate dehydrogenase (IDH)1 or IDH2 are seen in ~15–20% of patients with acute myeloid leukemia (AML). Mutant IDH (mIDH) reduces α-ketoglutarate to the oncometabolite 2-hydroxyglutarate ...

Date: 05 Mar 2018
Presenter: David Schenkein
Resources: Abstract, Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...erSaVax-the-road-so-far-and-the-future-ahead

The vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and immunosuppressive cascades inherent to tumor development. Success of drugs targeting this growth factor and their...

Date: 05 Mar 2018
Presenter: Mónica Bequet-Romero
Resources: Abstract, Presentation, Webcast
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...-immune-responses-against-established-tumors

Virus-based vaccines and appropriate costimulation enhance potent antigen-specific T cell immunity against cancer. In the present study we exploit both innate and adaptive immune responses triggered...

Date: 05 Mar 2018
Presenter: Jose Medina
Resources: Abstract, Presentation
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...ellular-carcinoma-in-Phase-I-clinical-trials

In Asia, chronic hepatitis B and C virus infections (CHVI) are major risk factors for liver fibrosis and hepatocellular carcinoma (HCC). Patients with advanced HCC have limited effective therapeutic...

Date: 05 Mar 2018
Presenter: Takafumi Koyama
Resources: Abstract
Topics: Hepatobiliary Cancers, Cancer in Special Situations

https://oncologypro.esmo.org/Meeting-Resour...Dylation-Pathway-in-Myelodysplastic-Syndrome

A phase I clinical trial of Pevonedistat (MLN4924), a NEDD8-activating enzyme inhibitor, in AML and MDS showed modest clinical activity as a single agent. A phase II trial with Pevonedistat plus...

Date: 05 Mar 2018
Presenter: Fatemeh Majidi
Resources: Abstract